Association between adefovir dipivoxil treatment and the risk of renal insufficiency in patients with chronic hepatitis B: A meta-analysis

Yang,Qiao; Shi,Yu; Yang,Ying; Lou,Guohua; Lv,Fangfang

doi:10.3892/br.2015.415

Association between adefovir dipivoxil treatment and the risk of renal insufficiency in patients with chronic hepatitis B: A meta-analysis

Authors:
- Qiao Yang
- Yu Shi
- Ying Yang
- Guohua Lou
- Fangfang Lv
View Affiliations

Affiliations: Department of Infectious Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016, P.R. China, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016, P.R. China
Published online on: January 7, 2015 https://doi.org/10.3892/br.2015.415
Pages: 269-275

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adefovir dipivoxil (ADV) is an effective antiviral drug against hepatitis B virus. The renal tolerance of ADV at the currently approved dose of 10 mg daily for the treatment of chronic hepatitis B (CHB) remains controversial. The present meta‑analysis was therefore performed to evaluate the renal safety of ADV treatment in patients with CHB. Two independent investigators searched MEDLINE, Embase and China National Knowledge Infrastructure databases for eligible studies published in English or Chinese until June 1, 2014. The Peto odds ratios (Peto ORs) or the rates of each study were analyzed. Seven randomized controlled trials (RCTs), four cohort studies and six single‑arm studies were identified. ADV treatment was not associated with a higher incidence of nephrotoxicity in RCTs [Peto OR, 1.781; 95% confidence interval (CI), 0.637‑4.979; P=0.271] but appeared to increase nephrotoxicity significantly in cohort studies (Peto OR, 2.682; 95% CI, 1.470‑4.894; P=0.001); the significant increase was further observed in CHB patients receiving long‑term ADV treatment in cohort studies (Peto OR, 2.275; 95% CI, 1.127‑4.593; P=0.022). The analysis based on single‑arm studies showed that the rate of renal dysfunction in the ADV‑treated patients was 10.6% (95% CI, 0.059‑0.185); the subgroup analysis with the standard of createnine levels showed a lower rate (6.9%, 95% CI, 0.013‑0.298) than those in the overall studies. In conclusion, although current evidence indicated a positive link between treatment with ADV in CHB patients and an increased risk of renal dysfunction, optimally designed studies are required for definitive conclusions.

View Figures

View References

1	Fisher EJ, Chaloner K, Cohn DL, et al: The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS. 15:1695–1700. 2001. View Article : Google Scholar : PubMed/NCBI
2	Dando T and Plosker G: Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs. 63:2215–2234. 2003. View Article : Google Scholar : PubMed/NCBI
3	Marcellin P, Chang TT, Lim SG, et al: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 348:808–816. 2003. View Article : Google Scholar : PubMed/NCBI
4	Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 348:800–807. 2003. View Article : Google Scholar : PubMed/NCBI
5	Tamori A, Enomoto M, Kobayashi S, et al: Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. J Viral Hepat. 17:123–129. 2010. View Article : Google Scholar : PubMed/NCBI
6	Marcellin P, Chang TT, Lim SG, et al: Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 48:750–758. 2008. View Article : Google Scholar : PubMed/NCBI
7	Pearce-Smith N and Hunter J: The introduction of librarian tutors into the Teaching Evidence-Based Medicine week in Oxford, UK. Health Info Libr J. 22:146–149. 2005. View Article : Google Scholar : PubMed/NCBI
8	Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 17:1–12. 1996. View Article : Google Scholar : PubMed/NCBI
9	Perrillo R, Hann HW, Mutimer D, et al: Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 126:81–90. 2004. View Article : Google Scholar : PubMed/NCBI
10	Izzedine H, Hulot JS, Launay-Vacher V, et al: Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int. 66:1153–1158. 2004. View Article : Google Scholar : PubMed/NCBI
11	Lim SG, Marcellin P, Tassopoulos N, et al: Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther. 26:1419–1428. 2007. View Article : Google Scholar : PubMed/NCBI
12	Jonas MM, Kelly D, Pollack H, et al: Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology. 47:1863–1871. 2008. View Article : Google Scholar : PubMed/NCBI
13	Manolakopoulos S, Striki A, Deutsch M, et al: Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBe Ag-negative chronic hepatitis B patients. Liver Int. 31:1525–1532. 2011. View Article : Google Scholar : PubMed/NCBI
14	Mauss S, Berger F, Filmann N, et al: Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol. 55:1235–1240. 2011. View Article : Google Scholar : PubMed/NCBI
15	Ha NB, Ha NB, Garcia RT, et al: Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology. 50:727–734. 2009. View Article : Google Scholar : PubMed/NCBI
16	Gu SW, Zhao B, Sun YY, et al: The effect of different doses of adefovir dipivoxil on renal function. Chin Hepatol. 15:247–250. 2010.(In Chinese).
17	Yu JH, Shi JP, Wu J, et al: Efficacy and safety of lamivudine plus adefovir combination therapy and entecavir monotherapy for chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi. 19:88–92. 2011.(In Chinese). PubMed/NCBI
18	Li X, Zhong C, Yang S, et al: Influence of adefovir dipivoxil or telbivudine monotherapy on renal function of patients with chronic hepatitis B. Nan Fang Yi Ke Da Xue Xue Bao. 32:826–829. 2012.(In Chinese). PubMed/NCBI
19	Lampertico P, Viganò M, Manenti E, et al: Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 133:1445–1451. 2007. View Article : Google Scholar : PubMed/NCBI
20	Vassiliadis TG, Giouleme O, Koumerkeridis G, et al: Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBe Ag-chronic hepatitis B patients: a 4-year study. J Gastroenterol Hepatol. 25:54–60. 2010. View Article : Google Scholar : PubMed/NCBI
21	Kim YJ, Cho HC, Sinn DH, et al: Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. J Gastroenterol Hepatol. 27:306–312. 2012. View Article : Google Scholar : PubMed/NCBI
22	Zhu MF, Qian JC, Lu L, et al: Three-year efficacy and side effect of adefovir dipivoxil for the treatment of the old patients with chronic hepatitis B virus infection. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 26:379–381. 2012.(In Chinese). PubMed/NCBI
23	Tanaka M, Suzuki F, Seko Y, et al: Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. J Gastroenterol. 49:470–480. 2014. View Article : Google Scholar : PubMed/NCBI
24	Peters MG, Hann HW, Martin P, et al: Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 126:91–101. 2004. View Article : Google Scholar : PubMed/NCBI
25	Seto WK, Liu K, Fung J, et al: Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. Antivir Ther. 17:1255–1262. 2012. View Article : Google Scholar : PubMed/NCBI
26	Schiff ER, Lai CL, Hadziyannis S, et al: Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology. 38:1419–1427. 2003. View Article : Google Scholar : PubMed/NCBI
27	Schiff E, Lai CL, Hadziyannis S, Neuhaus P, et al: Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 13:349–360. 2007. View Article : Google Scholar : PubMed/NCBI
28	Byar DP, Simon RM, Friedewald WT, et al: Randomized clinical trials. Perspectives on some recent ideas. N Engl J Med. 295:74–80. 1976. View Article : Google Scholar : PubMed/NCBI
29	Abel U and Koch A: The role of randomization in clinical studies: myths and beliefs. J Clin Epidemiol. 52:487–497. 1999.PubMed/NCBI
30	Benson K and Hartz AJ: A comparison of observational studies and randomized, controlled trials. N Engl J Med. 342:1878–1886. 2000. View Article : Google Scholar : PubMed/NCBI
31	Levey AS, Bosch JP, Lewis JB, et al: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 130:461–470. 1999. View Article : Google Scholar : PubMed/NCBI
32	Cockcroft DW and Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron. 16:31–41. 1976. View Article : Google Scholar : PubMed/NCBI
33	Levey AS, Stevens LA, Schmid CH, et al: A new equation to estimate glomerular filtration rate. Ann Intern Med. 150:604–612. 2009. View Article : Google Scholar : PubMed/NCBI
34	Lujan PR, Chiurchiu C, Douthat W, et al: CKD-EPI instead of MDRD for candidates to kidney donation. Transplantation. 94:637–641. 2012. View Article : Google Scholar : PubMed/NCBI